Naringenin Enhances the Inhibitory Effect of Regorafenib on HepG2 Hepatocellular Carcinoma Cell Viability with Modulation of E-Cadherin and MRP1 Gene Expression
4 affiliations
- 1Department of Biochemistry & Molecular Biology, Faculty of Pharmacy (Girls), Al-Azhar University, Nasr City, Cairo 11823, Egypt
- 2Department of Biochemistry and Molecular Biology, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, Cairo 11823, Egypt
- 3Department of Biochemistry, Faculty of Pharmacy, Heliopolis University, 3 Cairo-Belbeis Desert Road, El Salam, Cairo 11785, Egypt
- 4Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah Bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia
Abstract
Hepatocellular carcinoma (HCC) is a life-threatening malignancy. Although regorafenib is used for HCC treatment, its clinical utility is limited by significant adverse effects. This study evaluated whether combining regorafenib with naringenin could enhance its anticancer activity against HepG2 cells. This study included seven groups of HepG2 cancer cells: an untreated control group, a naringenin-treated group (100 μM), a regorafenib-treated group (1 μM), and four groups receiving naringenin (100 μM) combined with decreasing concentrations of regorafenib (1, 0.75, 0.5, and 0.25 μM). Cell viability and the expression of E-cadherin and MRP1 were assessed. All treatments significantly reduced cell viability compared with the control group, with greater inhibition observed in the combination-treated groups than in the monotherapy groups. Combination treatment also increased E-cadherin expression and decreased MRP1 expression. The combination of regorafenib (1 μM) and naringenin (100 μM) exhibited the greatest growth inhibition, the highest E-cadherin, and the lowest MRP1 expression levels. Notably, combining the IC50 of naringenin with one-quarter of the regorafenib IC50 significantly enhanced E-cadherin expression and reduced MRP1 expression compared with regorafenib alone. The present findings suggest that naringenin enhances the anticancer effects of regorafenib in HepG2 cells and modulates E-cadherin and MRP1 gene expression.
Related
- Potential Effects of Naringenin on Hepatic Lipid Accumulation and Lipogenesis-Related Gene Expression in High-Fat Diet-Fed Rats
- Effect of food-cues on aMCC glutamate modulation during inhibitory control post weight loss intervention: a 1H fMRS study
- Gilteritinib Suppresses Hepatocellular Carcinoma Cells in Association with Reduced Calpain-1 Expression and Inhibition of STAT3/AKT Signaling
- Therapeutic potential of natural product polysaccharides in hepatocellular carcinoma: from microenvironment modulation to combination strategies
- MCH-02, a synthetic macamide analog with in vitro FAAH-inhibitory activity, modulates hippocampal endocannabinoid system and BK channel expression without preventing PTZ-induced progressive seizure susceptibility in rats
BibTeX
@article{gaballah2026naringenin,
title = {{Naringenin Enhances the Inhibitory Effect of Regorafenib on HepG2 Hepatocellular Carcinoma Cell Viability with Modulation of E-Cadherin and MRP1 Gene Expression}},
author = {Sara A. Gaballah and Ahmed I. Abulsoud and Asmaa Saleh and Noha A. Eldesoky},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27209347},
url = {https://www.mdpi.com/1422-0067/27/20/9347},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Naringenin Enhances the Inhibitory Effect of Regorafenib on HepG2 Hepatocellular Carcinoma Cell Viability with Modulation of E-Cadherin and MRP1 Gene Expression
AU - Sara A. Gaballah
AU - Ahmed I. Abulsoud
AU - Asmaa Saleh
AU - Noha A. Eldesoky
PY - 2026
DA - 2026/10/01
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27209347
UR - https://www.mdpi.com/1422-0067/27/20/9347
AB - Hepatocellular carcinoma (HCC) is a life-threatening malignancy. Although regorafenib is used for HCC treatment, its clinical utility is limited by significant adverse effects. This study evaluated whether combining regorafenib with naringenin could enhance its anticancer activity against HepG2 cells. This study included seven groups of HepG2 cancer cells: an untreated control group, a naringenin-treated group (100 μM), a regorafenib-treated group (1 μM), and four groups receiving naringenin (100 μM) combined with decreasing concentrations of regorafenib (1, 0.75, 0.5, and 0.25 μM). Cell viability and the expression of E-cadherin and MRP1 were assessed. All treatments significantly reduced cell viability compared with the control group, with greater inhibition observed in the combination-treated groups than in the monotherapy groups. Combination treatment also increased E-cadherin expression and decreased MRP1 expression. The combination of regorafenib (1 μM) and naringenin (100 μM) exhibited the greatest growth inhibition, the highest E-cadherin, and the lowest MRP1 expression levels. Notably, combining the IC50 of naringenin with one-quarter of the regorafenib IC50 significantly enhanced E-cadherin expression and reduced MRP1 expression compared with regorafenib alone. The present findings suggest that naringenin enhances the anticancer effects of regorafenib in HepG2 cells and modulates E-cadherin and MRP1 gene expression.
SN - 1422-0067
ER -